'I feel like I'm behind on retirement. I spent way too many years financially supporting a toxic parent.' ...
Allurion Technologies, Inc. ("Allurion" or the "Company") , a company dedicated to ending obesity, today announced initial results on the combination of the Allurion Program with low-dose GLP-1 ...
MedPage Today on MSN2d
Type 2 Diabetes Patients Also Reap Benefits of Automated Insulin DeliveryOver 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...
MT Newswires on MSN1d
Wall Street Set to Open Lower Friday as Investors Look to End Losing Week StreakUS stocks look set to open lower in Friday's trading session but are still in a position to close out the week higher for the first time in over a month. The Dow Jones Industrial Average futures were ...
who brings over 40 years of compounding experience across both 503A and 503B sectors. ProRx also recently welcomed a new head of its Quality Assurance unit, who previously served in the quality ...
Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...
The “trendification” of Ozempic and semaglutide is putting immense pressure ... With approximately 40% of the US population struggling with obesity, the pool of potential GLP-1 users has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback